Plain-English translation of NCT07191847 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing CaraClear, a new type of eye drop made with stem cells, to see if it can help people with dry eye disease and corneal cloudiness. Dry eye is a common condition that causes discomfort, blurred vision, and can damage the surface of your eye. The researchers want to find out whether this medication can improve tear production, stabilize your tear film, and reduce symptoms over 12 weeks.
Dry eye disease affects millions of people worldwide and can seriously impact quality of life, yet many existing treatments don't work well enough. This trial exists to see whether a stem cell-based approach might offer a new and more effective way to treat dry eye and help restore corneal clarity.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will apply the study to your eyes three times per day for 12 weeks. Researchers will monitor your tear film stability, tear volume, and dry eye symptoms throughout the study to see how well the medication works. You'll need to attend clinic visits so the team can examine your eyes and track your progress.
AI-generated summary from trial data · Aug 30, 2026 · Not medical advice
Egypt
Post-approval monitoring
Sponsor
Ace Cells Lab Limited
Collaborators
University of Nottingham
Enrollment target
~300 participants
Started
April 2025
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dr. Alaa Abdelkarim DAF Fouad, MD, MBBCHConsultant stem cells
Beni-Suef University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.